Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males. / Skov, Jeppe; Holst, Jens Juul; Gøtze, Jens Peter; Frøkiær, Jørgen; Christiansen, Jens Sandahl.

In: Endocrine Connections, Vol. 3, No. 1, 2014, p. 11-6.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Skov, J, Holst, JJ, Gøtze, JP, Frøkiær, J & Christiansen, JS 2014, 'Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males', Endocrine Connections, vol. 3, no. 1, pp. 11-6. https://doi.org/10.1530/EC-13-0087

APA

Skov, J., Holst, J. J., Gøtze, J. P., Frøkiær, J., & Christiansen, J. S. (2014). Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males. Endocrine Connections, 3(1), 11-6. https://doi.org/10.1530/EC-13-0087

Vancouver

Skov J, Holst JJ, Gøtze JP, Frøkiær J, Christiansen JS. Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males. Endocrine Connections. 2014;3(1):11-6. https://doi.org/10.1530/EC-13-0087

Author

Skov, Jeppe ; Holst, Jens Juul ; Gøtze, Jens Peter ; Frøkiær, Jørgen ; Christiansen, Jens Sandahl. / Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males. In: Endocrine Connections. 2014 ; Vol. 3, No. 1. pp. 11-6.

Bibtex

@article{3b9f93c84082448da2786f3fcf431ebf,
title = "Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males",
abstract = "The antihypertensive actions of glucagon-like peptide-1 (GLP1) receptor agonists have been linked to the release of atrial natriuretic peptide (ANP) in mice. Whether a GLP1-ANP axis exists in humans is unknown. In this study, we examined 12 healthy young males in a randomized, controlled, double-blinded, single-day, cross-over study to evaluate the effects of a 2-h native GLP1 infusion. Plasma proANP concentrations were measured by an automated mid-region-directed proANP immunoassay and N-terminal pro B-type natriuretic peptide (BNP) on Roche Modular E170. Urine was collected for measurements of sodium excretion. Although GLP1 infusion increased the urinary sodium excretion markedly, there were no significant changes in either proANP or proBNP concentrations. When GLP1 infusion was stopped, sodium excretion declined rapidly. As proANP concentration reflects ANP secretion, our data could not confirm the existence of a GLP1-ANP axis in humans. Especially, the natriuretic effects of GLP1 seem unlikely to be mediated exclusively via ANP.",
author = "Jeppe Skov and Holst, {Jens Juul} and G{\o}tze, {Jens Peter} and J{\o}rgen Fr{\o}ki{\ae}r and Christiansen, {Jens Sandahl}",
year = "2014",
doi = "10.1530/EC-13-0087",
language = "English",
volume = "3",
pages = "11--6",
journal = "Endocrine Connections",
issn = "2049-3614",
publisher = "BioScientifica Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males

AU - Skov, Jeppe

AU - Holst, Jens Juul

AU - Gøtze, Jens Peter

AU - Frøkiær, Jørgen

AU - Christiansen, Jens Sandahl

PY - 2014

Y1 - 2014

N2 - The antihypertensive actions of glucagon-like peptide-1 (GLP1) receptor agonists have been linked to the release of atrial natriuretic peptide (ANP) in mice. Whether a GLP1-ANP axis exists in humans is unknown. In this study, we examined 12 healthy young males in a randomized, controlled, double-blinded, single-day, cross-over study to evaluate the effects of a 2-h native GLP1 infusion. Plasma proANP concentrations were measured by an automated mid-region-directed proANP immunoassay and N-terminal pro B-type natriuretic peptide (BNP) on Roche Modular E170. Urine was collected for measurements of sodium excretion. Although GLP1 infusion increased the urinary sodium excretion markedly, there were no significant changes in either proANP or proBNP concentrations. When GLP1 infusion was stopped, sodium excretion declined rapidly. As proANP concentration reflects ANP secretion, our data could not confirm the existence of a GLP1-ANP axis in humans. Especially, the natriuretic effects of GLP1 seem unlikely to be mediated exclusively via ANP.

AB - The antihypertensive actions of glucagon-like peptide-1 (GLP1) receptor agonists have been linked to the release of atrial natriuretic peptide (ANP) in mice. Whether a GLP1-ANP axis exists in humans is unknown. In this study, we examined 12 healthy young males in a randomized, controlled, double-blinded, single-day, cross-over study to evaluate the effects of a 2-h native GLP1 infusion. Plasma proANP concentrations were measured by an automated mid-region-directed proANP immunoassay and N-terminal pro B-type natriuretic peptide (BNP) on Roche Modular E170. Urine was collected for measurements of sodium excretion. Although GLP1 infusion increased the urinary sodium excretion markedly, there were no significant changes in either proANP or proBNP concentrations. When GLP1 infusion was stopped, sodium excretion declined rapidly. As proANP concentration reflects ANP secretion, our data could not confirm the existence of a GLP1-ANP axis in humans. Especially, the natriuretic effects of GLP1 seem unlikely to be mediated exclusively via ANP.

U2 - 10.1530/EC-13-0087

DO - 10.1530/EC-13-0087

M3 - Journal article

C2 - 24327600

VL - 3

SP - 11

EP - 16

JO - Endocrine Connections

JF - Endocrine Connections

SN - 2049-3614

IS - 1

ER -

ID: 117852866